Kyverna Therapeutics
Healthcare & Life Sci
Company overview
Kyverna Therapeutics is a late-stage clinical biopharmaceutical company founded in 2018. It develops CD19-targeting CAR T-cell therapy for severe autoimmune diseases driven by B cells. Its lead candidate, miv-cel, is in a rolling Biologics License Application submission for stiff person syndrome.
Gilead Sciences has been a strategic partner since January 2020, when it paid $17.5 million upfront as part of a collaboration deal. That backing supports Kyverna's work as it moves candidates through late-stage development. Kyverna Therapeutics is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- United States